Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients

Fabry Disease Clinical Trial

Official title:

Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05056636
• Other study ID #: GZ201711687
• Status: Recruiting
• Start date: June 1, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: September 2021
• Source: Chang Gung Memorial Hospital
• Contact: Chien-Hsing Wu, MD
• Phone: +886975056082
• Email: chienhsingwu[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene.

It is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The α-Gal A deficiency results in progressive accumulation of un-degraded glycosphingolipids, predominantly globotriaosylceramide (Gb3), within cell lysosomes throughout the body.

In patients at the second or third decade, progressive proteinuria, decline in glomerular filtration rate (GFR), and tubular damage occur usually, and renal failure develops in the fourth decade. Life-threatening renal, cardiac, and cerebrovascular diseases are added in later decades.

In addition to that, Fabry disease patient will eventually face end-stage renal disease (ESRD) which was the most common cause of death in Fabry patients before the development of dialysis and renal transplantation. Thus it is critical to identify Fabry patient as early as possible, before reaching the stage of ESRD.

Additionally, early intervention of enzyme replacement therapy for Fabry Disease patient which will help the patient to preserve a better renal function and benefit from treatment outcome.

Apart from that today there is only one study published from Turkey for Fabry disease screening in CKD patient where they have screened 1453 and found that the overall prevalence of Fabry disease in CKD patient was found to be 0.2% , 3/1453 (in which 0.4% in 656 male, 0.0% in 783 female). However, there was no information available within the Asia region thereby a very low Fabry disease awareness and diagnostic awareness among nephrologist in Taiwan.

Therefore in the present study the investigators are aiming to investigate the prevalence of Fabry disease in the CKD population (CKD stage 1 ~ 5) by conducting the first and largest high risk screening prevalence study among 2,000 CKD patients over 3 years in Taiwan and the investigators hope by doing such a pilot study our data would contribute to a new paradigm of Fabry disease diagnosis in the Asia region.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: December 31, 2022
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient age = 18 y/o (No age limit due to cardiac variant Fabry IVS4 in Taiwan symptom of onset could be beyond 60 y/o)

• Patient with confirmed chronic kidney disease (CKD 1~5) diagnosis whose urine protein/creatinine (UPCR) is 150mg/g or above, or urine albumin/creatinine (ACR) is 30mg/g or above.

• Patient who are willing to sign inform consent form

Exclusion Criteria:

• Patient who are unwilling to sign inform consent form

• Patient who received confirmed diagnosis of Fabry Disease

• Patient with known etiology of renal failure diagnosed with renal biopsy.

Related Conditions & MeSH terms

• Fabry Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Diagnostic Test:
• Plasma a-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.
Screening Visit 1: Male patient will first screened by enzymatic assay (Cutoff: 1.3 µM /hr) Female patient will first screened by lyso-GB3 (Cutoff: > 5ng/ml) Screening Visit 2: If both male and female who has deficient enzymatic level (Cutoff: 1.3 µM /hr) or lyso-GB3 level (Cutoff: > 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing.

Locations

Country	Name	City	State
Taiwan	Chang Gung Memory Hospital	Kaohsiung

Sponsors (1)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive screening rate of Fabry Disease patient among CKD population	Identify the prevalence rate of Fabry disease in patients with CKD including dialysis in Taiwan.	48 months
Secondary	Characterization of gene mutation pattern of Fabry patients with CKD in Taiwan	Identify what gene mutation(s) is(are) significant associated with Fabry patients with CKD in Taiwan	48 months